Allston, MA – According to filings with the U.S. Securities and Exchange Commission, Elevian is raising $42,719,318.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Allen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elevian
At Elevian, we develop new medicines to restore regenerative capacity, with the potential to prevent and treat many age-related diseases. Our mission is to help people age, unburdened by the diseases of aging. Groundbreaking research at our labs and others has demonstrated that older animals, when transfused with the blood of young animals, experience regeneration across many tissues and organs. The opposite is also true: young animals, when transfused with the blood of older animals, experience accelerated aging. Elevians scientific founders identified specific circulating factors that may be responsible for these effects. One example, a naturally occurring molecule known as growth differentiation factor 11 (GDF11), when injected into aged mice, reproduces many of the regenerative effects of young blood. GDF11 supplementation reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, improves exercise capacity, improves brain function and cerebral blood flow, and improves metabolism. Our founders discoveries are published in leading journals and were recognized by Science as a global top 10 scientific breakthrough of 2014. Elevian is developing a number of therapeutics that regulate GDF11 and other circulating factors, in order to restore our bodys natural regenerative capacity, which we believe address a root cause of age-associated diseases.

To learn more about Elevian, visit http://www.elevian.com/

Contact:
Mark Allen, Chief Executive Officer
650-906-9466
mark@elevian.com
https://www.linkedin.com/in/markallenmd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved